Maplirpacept

研究CD47抑制剂的生物制药公司，最近大多过的不太好。吉利德在其CD47靶向抗体Magrolimab上的数十亿美元赌注岌岌可危；艾伯维最近结束了与另一种抗CD47药物生产商天境生物的合作，并在去年8月终止了该候选药物的两项早期临床研究。CD47这个曾经看起来竞争激烈的领域，如今正是四面楚歌。一些业内人士推测，CD47抗体药物可能存在致命的缺陷。被认为是下一个PD-1CD47是一种广泛表达的跨膜糖蛋白，广泛表达于体细胞表面，可与信号调节蛋白 α (SIRP α)、血小板反应蛋白 (TSP1) 以及整合素相互作用，介导凋亡、增殖、免疫等一系列反应。其作用机制是与巨噬细胞表面的SIRPα结合，形成CD47-SIRPα信号复合物，进而促进“别吃我”信号的释放，这些信号抑制巨噬细胞介导的吞噬作用，保护正常细胞免受免疫系统的损害。癌细胞利用这个“被吃我”信号机制，在肿瘤细胞表面表达高水平的CD47,实现免疫逃逸。研究者认为抑制癌细胞中 CD47 信号可能促进巨噬细胞对肿瘤细胞的吞噬，从而限制肿瘤生长，这为抗肿瘤治疗提供了新的可行的免疫靶点。由于CD47的作用机制与PD-1类似，又能广泛表达在不同的癌细胞，所以CD47被看成是下一个PD-1。全球药企都希望再现PD-1的传奇，从CD47赛道中挖出下一个“全球药王”。据统计，目前全球已有超百款针对CD47靶点的药物处于临床研究阶段，涉及单抗、双抗和融合蛋白等药物类型。其中，仅国内就有36款产品进入临床阶段，涉及天境生物、康方生物和信达生物等超30家药企。不过，由于CD47容易出现安全性问题，研发失败率高，至今没有一款CD47靶向药物能获批上市。难以解决的安全性难题CD47药物研发遇到的第一个问题就是对红细胞的误伤，这是因为CD47不仅表达于肿瘤细胞，还表达于正常的红细胞表面，在正常生理条件下主导红细胞在体内的清除和平衡。在杀伤肿瘤时会波及到红细胞，引发贫血、血小板减少症等血液毒性问题。第一代CD47单抗如Arch Oncdogy公司的Ti-061、新基公司的CC-90002以及Surface Oncology公司的SFR231均由于严重的血液不良反应而被迫终止开发。自此，行业内对CD47药物的成药价值产生了严重质疑。直到2019年，Forty Seven公司展示了其自行研发的IgG4 CD47单抗Hu5F9-G4（Magrolimab）的临床数据，优秀的疗效重新燃起了行业内对CD47的希望。为了解决细胞毒素问题，各大药企采用了不同的研发策略。其中抗体亚型的选择是一大关键，一般而言，针对免疫细胞上靶点，多选IgG4抗体，如K药、O药；针对肿瘤细胞表面靶点，多选择IgG1抗体，如美罗华、赫赛汀等。由于CD47在肿瘤细胞表面表达，理论上应选择Fc效应器功能最强的IgG1型抗体，但由于CD47在正常细胞中的广泛表达，IgG1抗体血液毒性问题可能难以解决。IgG1单药可以展现出一定的抗肿瘤活性，但可能存在安全性问题。而临床上，Fc效应器功能较弱的IgG4、IgG2亚型单抗单药基本无效，多以联合用药为主。Magrolimab就是选择在Fc端采用IgG4亚型而非IgG1亚型，通过削弱抗体的杀伤力来实现减毒目标，并选择联合化疗药物阿扎胞苷，但是结果也是差强人意。一些药企开始将注意力落在了针对CD47亲和力的改造策略和双抗的尝试上。所谓针对CD47亲和力的改造策略，其实就是只结合肿瘤细胞的CD47，不结合红细胞等正常组织的CD47，实现方式有两种：要么利用特殊的SIRPα结合CD47的结构域，要么筛选只针对肿瘤CD47的特殊偏向性抗体。例如，辉瑞斥资22.6亿美元收购的Trillium Therapeutics，以及国内药企宜明昂科、天境生物和康方生物，都是采取这种策略来研发CD47药物。但是不管是哪种策略都会面临新的问题。药企相继折戟对于CD47来说，最严峻的一个问题是，一些生物科技巨头付出了很多努力，都无法将其转化为有效的治疗方法。鉴于Magrolimab让行业看到了新希望，2020年3月，吉利德发布公告称，将支付49亿美元现金来收购Forty Seven，获得该公司旗下的Magrolimab。随后更多的热钱涌入其中，艾伯维与天境生物达成了协议，辉瑞以22.2亿美元收购了两种抗CD47蛋白的生产商Trillium Therapeutics。但是大厂们的入局，以及相继的碰壁，又给CD47的药物研发泼上了冷水。去年1月份，由于研究人员报告的可疑意外严重不良反应（SUSARs）在各研究组间存在明显的不平衡，FDA部分暂停了吉利德Magrolimab+阿扎胞苷的联合研究。虽然3个月后，FDA解除了临床搁置，但是几个月后的八月份，Magrolimab再次因为临床疗法问题碰壁，一项Ib期研究发现，在接受Magrolimab+阿扎胞苷治疗的AML患者中，28.7%发生了与抗CD47药物相关的贫血。今年7月份，吉利德因疗效问题，终止CD47单抗Magrolimab联合阿扎胞苷治疗高风险MDS的III期ENHANCE研究；8月份，FDA暂停了Magrolimab在AML患者中的部门临床试验；9月底，吉利德宣布停止Magrolimab用于TP53突变急性髓系白血病（AML）的ENHANCE-2研究，原因是与现有标准治疗相比，Magrolimab在TP53突变的AML患者中显示出生存获益的可能性并不大。今年9月，艾伯维全面终止与天境生物就CD47单抗在研药物——来佐利单抗等产品的合作协议。但其实在去年艾伯维就有想要终止合作的迹象，2022年8月，艾伯维就决定停止来佐利单抗联合阿扎胞苷和维奈托克治疗MDS和AML的全球1b期临床试验。一些好消息今年10月份，ALX Oncology公布了其CD47单抗Evorpacept治疗Her2阳性胃癌的Ⅱ期临床试验的中期数据，并宣布将在2024年下半年进入III期试验，扭转了该领域近期的颓势。ALX首席执行官Jason Lettmann表示这一积极的结果证明了抗CD47疗法的故事仍在继续。与吉利德的Magrolimab选择在Fc端采用不同亚型的策略不同的是，ALX Oncology采取让“Fc域”灭活的策略。由于失活突变的Fc域无法募集巨噬细胞，因而不会对红细胞造成伤害。放弃CD47抗体引发的杀伤作用，仅利用其将肿瘤细胞充分暴露，联合其他疗法杀死肿瘤。10月3日，ALX宣布其CD47抑制剂Evorpacept（ALX-148）联合曲妥珠单抗、雷莫西尤单抗和紫杉醇治疗HER2阳性胃或为食管交界处（GEJ）癌患者的国际多中心ASPEN-06试验在预先指定的2期部分中期分析中获得积极结果。接受Evorpacept +曲妥珠单抗、雷莫西尤单抗+紫杉醇联合治疗的ORR为52%，而仅接受后三种药物治疗的对照组为22%。ALX计划明年报告该试验的最终分析结果。ALX也并非一帆风顺，该公司最近取消了Evorpacept用于治疗骨髓增生异常综合征（MDS）和急性髓系白血病（AML）的CD47项目。ALX解释说，Evorpacept在这两种血液癌症中的作用机制不同于在实体瘤中的作用机制。在针对CD47亲和力的改造策略方面，也有一些好消息传出。辉瑞收购的Trillium改造策略是利用特殊的SIRPα结合CD47的结构域，通过天然变体V2的Domain1（一种特殊的SIRPα亚型）来结合肿瘤细胞表面的CD47，研发了针对IgG1的TTI-621和针对IgG4的TTI-622两种均没有红细胞毒性的融合蛋白管线。近日，辉瑞的发言人对外表示其抗CD47候选药物Maplirpacept已经显示出与红细胞结合最少的情况，并且很少有贫血的报告病例。该发言人说，Maplirpacept对癌细胞和巨噬细胞都有作用，在超过75例患者的研究中，Maplirpacept作为单药疗法显示出“令人鼓舞的活性”。目前，辉瑞正在进行卵巢癌、多发性骨髓瘤和弥漫性大b细胞淋巴瘤的I期和II期试验。国内的药企也在各自的策略下顺利推进中。宜明昂科也是采用特殊的SIRPα结合CD47的结构域策略，目前，公司布局了7款CD47药物，其中进度最快的IMM01正在推进多项联合疗法；天境生物和康方生物选择筛选只针对肿瘤CD47的特殊偏向性抗体的改造策略，天境生物的来佐利单抗已于2023年4月在中国启动了治疗MDS的Ⅲ期临床研究。康方生物莱法利单抗是目前国内唯一针对三阴乳腺癌适应症的CD47靶向药物，联合阿扎胞苷治疗MDS的随机、双盲、全球多中心II期临床研究已于9月26日获FDA批准。还有一些企业在尝试双抗的研发，包括CD47/PD-L1双抗（如迈威生物的6MW3211、百奥泰的BAT7104）和CD47/CLDN18.2双抗（如康方的AK132、宝船生物的BC007）。虽然艰难坎坷一直都在，但是各个药企都在自己的创新之路上奔跑。参考来源：1.https://www.biospace.com/article/embattled-researchers-see-path-forward-for-anti-cd47-cancer-drugs/2.https://baijiahao.baidu.com/s?id=1779146583620953723&wfr=spider&for=pc3.https://mp.weixin.qq.com/s?__biz=MzA4MzgzMDM5Mg==&mid=2651739174&idx=3&sn=056c6cc0bfbf749fbf5b42bdd97f4b40&chksm=840a8731b37d0e275dc824bb6ea94925ca05d4164f5a5da489151cda3be59feb08fddd65aacc&scene=274.https://baijiahao.baidu.com/s?id=1779171563869776831&wfr=spider&for=pc5.https://it.sohu.com/a/713979727_1211245436.https://weixin.sogou.com/weixin?query=CD47&_sug_type_=&sut=1519&lkt=5%2C1698737045086%2C1698737046345&s_from=input&_sug_=y&type=2&sst0=1698737046455&page=2&ie=utf8&w=01019900&dr=1

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH 2023 presentations will highlight new findings from the Phase 2 MANIFEST study of pelabresib and clinical and preclinical studies of tafasitamab PLANEGG and MUNICH GERMANY / ACCESSWIRE / November 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in San Diego, California, from December 9 to 12, 2023. "Pelabresib represents an opportunity to meaningfully improve the standard of care for patients with myelofibrosis, a community in dire need of more effective and well-tolerated treatment options," said Tim Demuth, M.D., Ph.D., MorphoSys Chief Research and Development Officer. "We will be sharing topline results from our pivotal MANIFEST-2 study in the coming weeks and look forward to presenting detailed findings at ASH 2023 shortly thereafter. We are very excited about the potential of pelabresib and grateful for the efforts of everyone who is contributing to this research - the investigators, clinical trial staff members, our employees and, most importantly, every patient and caregiver." MANIFEST-2 is a global, multicenter, double-blind, Phase 3 study investigating pelabresib in combination with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (those who have not been previously treated with a JAK inhibitor). A total of 431 patients were randomized in the study, making it one of the largest myelofibrosis studies conducted to date. The primary endpoint of the study is the proportion of patients who achieve a 35% or greater reduction in spleen volume (SVR35) from baseline at 24 weeks. A key secondary endpoint is the proportion of patients achieving a 50% or greater improvement in total symptom score (TSS50), as measured by the Myelofibrosis Symptom Assessment Form v4.0, from baseline at 24 weeks. The study is also assessing the absolute change in total symptom score (TSS) from baseline at week 24, percentage change in TSS from baseline at week 24, progression-free survival, overall survival, duration of the splenic and total symptom score responses, and improvement in bone marrow fibrosis, among other endpoints. One additional abstract on pelabresib and six abstracts on tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, were accepted for presentation and publication at ASH 2023. ASH 2023 Accepted Abstracts Abstracts listed below include both MorphoSys-led and partner abstracts. Abstract Title Abstract Number Date/Time Pelabresib ORAL Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study #628 Sunday, December 10, 4:30 p.m. - 6:00 p.m. PST / Monday, December 11, 1:30 a.m. - 3:00 a.m. CET Presentation Time: 5:15 p.m. PST POSTER Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data #3195 Sunday, December 10, 6:00 p.m. - 8:00 p.m. PST / Monday, December 11, 3:00 a.m. - 5:00 a.m. CET Tafasitamab ORAL Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the US Real-World Setting #265 Saturday, December 9, 2:00 p.m. - 3:30 p.m. PST / 11:00 p.m. - 12:30 a.m. CET Presentation Time: 2:00 p.m. PST POSTER Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States #2415 Saturday, December 9, 5:30 p.m. - 7:30 p.m. PST / Sunday, December 10, 2:30 a.m. - 4:30 a.m. CET POSTER Tafasitamab in Combination with a CD20xCD3 Bispecific T-cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models #2813 Sunday, December 10, 6:00 p.m. - 8:00 p.m. PST / Monday, December 11, 3:00 a.m. - 5:00 a.m. CET PUBLICATION realMIND: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, With a Focus on Patients from Minority Groups N/A N/A PUBLICATION Estimates of Survival and Life Expectancy with Tafasitamab plus Lenalidomide in the L-MIND Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma N/A N/A PUBLICATION A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-cell Lymphoma N/A N/A MorphoSys Events at ASH 2023 MorphoSys will host an in-person investor event with the company's management team and medical experts to review the detailed findings of the Phase 3 MANIFEST-2 study. The event, taking place on Monday, December 11, at the Hilton Bayfront Hotel, will start with a networking breakfast at 6:30 a.m. PST and continue with a formal presentation at 7:00 a.m. PST (10:00 a.m. EST / 4:00 p.m. CET). A webcast will also be available for those not attending ASH 2023 in person, accessible on the Investors section of MorphoSys' website ( ). Please refer to the ASH 2023 online program for full session details and data presentation listings and visit the MorphoSys booth (#2405) onsite. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at and follow us on Twitter at X and LinkedIn. About Pelabresib Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been approved by any regulatory authorities. Its safety and efficacy have also not been established in a pivotal trial. The development of pelabresib was funded in part by The Leukemia and Lymphoma Society®. About MANIFEST-2 MANIFEST-2 (NCT04603495) is a global, multicenter, double-blind, randomized Phase 3 clinical trial with pelabresib in combination with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (those who have not been previously treated with a JAK inhibitor). The primary endpoint of the study is a 35% or greater reduction in spleen volume (SVR35) from baseline at 24 weeks. A key secondary endpoint is a 50% or greater improvement in total symptom score (TSS50), as measured by the Myelofibrosis Symptom Assessment Form v4.0, from baseline at 24 weeks. The study is also measuring the absolute change in total symptom score (TSS) at week 24, percent change in TSS at week 24, progression-free survival, overall survival, duration of the splenic and total symptom score responses, and improvement in bone marrow fibrosis, among other endpoints. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. About MANIFEST MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis and high-risk essential thrombocythemia. The MANIFEST trial is evaluating pelabresib in combination with ruxolitinib in JAK-inhibitor-naïve myelofibrosis patients (Arm 3), with a primary endpoint of the proportion of patients with a ≥35% spleen volume reduction from baseline (SVR35) after 24 weeks of treatment. The trial is also evaluating pelabresib either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1) or as add-on therapy in combination with ruxolitinib in patients with a suboptimal response to ruxolitinib or myelofibrosis progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on transfusion-dependent (TD) status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a ≥35% spleen volume reduction from baseline after 24 weeks of treatment. The study is also evaluating pelabresib as a monotherapy in patients with high-risk essential thrombocythemia who are intolerant of, or refractory to, hydroxyurea (Arm 4). The primary endpoint for patients in Arm 4 is complete hematological response rate after one cycle, or 21 days, of treatment. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST trial sponsor. About Myelofibrosis Myelofibrosis, which belongs to a group of diseases called myeloproliferative disorders, is a difficult-to-treat form of blood cancer that's characterized by bone marrow fibrosis (a buildup of scar tissue in the bone marrow), spleen enlargement and anemia (low red blood cell counts) often requiring periodic blood transfusions. Patients with myelofibrosis can also suffer from a range of physical symptoms, including severe fatigue, night sweats, itching, increased bleeding and significant pain caused by their enlarged spleen. For many living with myelofibrosis, the combination of symptoms often severely impacts their quality of life. At diagnosis, several factors, such as age, genetics and bloodwork, help determine a patient's long-term prognosis. About 90% of newly diagnosed patients have intermediate- to high-risk disease, which has a worse prognosis and a higher likelihood of disease-associated symptoms. Today, myelofibrosis treatments revolve around the use of medications called JAK inhibitors, which can improve spleen size, anemia and general symptoms of myelofibrosis but do not address all four hallmarks of the disease. Only about 50% of patients treated with JAK inhibitors achieve adequate symptom control, and, unfortunately, that relief fades with time for many. Patients suffering from myelofibrosis are in critical need of new treatment options. About Monjuvi® (tafasitamab-cxix) Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). In the United States, Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Please see the U.S. full Prescribing Information for Monjuvi for important safety information. In Europe, Minjuvi® (tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials. Its safety and efficacy for these investigational uses have not been established in pivotal trials. Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi® in the U.S., and marketed by Incyte under the brand name Minjuvi® in Europe and Canada. XmAb® is a registered trademark of Xencor, Inc. U.S. Important Safety Information What are the possible side effects of MONJUVI? MONJUVI may cause serious side effects, including: - Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI. - Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or any bruising or bleeding. - Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or develop any signs and symptoms of an infection. The most common side effects of MONJUVI include: - Feeling tired or weak - Diarrhea - Cough - Fever - Swelling of lower legs or hands - Respiratory tract infection - Decreased appetite These are not all the possible side effects of MONJUVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you: -Have an active infection or have had one recently. - Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby. -You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI. -Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI. -Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI. You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or . You may also report side effects to MORPHOSYS US INC. at (844) 667-1992. Please see the full U.S. Prescribing Information for MONJUVI, including Patient Information, for additional Important Safety Information. Forward Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact: Media Contacts: Thomas Biegi Vice President Tel: +49 (0)89 / 89927 26079 thomas.biegi@morphosys.com Investor Contacts: Dr. Julia Neugebauer Head of Investor Relations Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Eamonn Nolan Director Tel: +1 617-548-9271 eamonn.nolan@morphosys.com SOURCE: MorphoSys AG View source version on accesswire.com: